NEWS
We’re Hiring!
MPN NEWS | September 21, 2021
Senior Manager/Associate Director of Research Programs MPN Research Foundation seeks an innovative, pragmatic, and collaborative Senior Manager or Associate Director (depending on experience) to manage our portfolio of research programs. The Foundation has a 20+year track record of impact on advancing disease knowledge and has influenced the evolving landscape of these rare blood cancers that… Read More »We’re Hiring!
Save the Date: Women & MPN
MPN NEWS | August 30, 2021
Save the date for the 7th Annual Women & MPN conference, hosted in person in Washington, D.C. on September 24th, 2021 from 9:00 AM – 3:00 PM EST. MPN Research Foundation Executive Director Kapila Viges will be there to participate along with this impressive line-up of speakers: Dr. Ruben Mesa, UT Health San Antonio Dr. Ellen Ritchie, Weill Cornell Med Dr. Michele Couri, University of Illinois Dr. Laura… Read More »Save the Date: Women & MPN
Recordings Available from Texas Virtual MPN Workshop
MPN NEWS | August 30, 2021
The recent Texas Virtual MPN Workshop: Second Annual Workshop and Meeting featured 30 speakers, including several whose research we funded, with participants from 77 countries. The presentations and panel discussions focused heavily on new and emerging clinical science on topics ranging from the very earliest stages of disease, including genetic predisposition to MPN, to strategies… Read More »Recordings Available from Texas Virtual MPN Workshop
NEWSLETTER ARCHIVE
MPN NEWS | July 21, 2021
Click HERE to subscribe and receive future editions of our Under the Microscope electronic publication and/or our print newsletter, MPN Update, conveniently delivered to your email or home mailbox! 2022: Fall | Summer | Spring 2021: Fall | Summer | Spring 2020: Fall | Summer | Spring 2019: Fall | Spring 2018: Fall | Spring 2017: Fall | Spring 2016: Fall | Spring 2015: Fall | Spring 2014: Fall | Spring 2013: Fall | Spring 2012: Fall | Spring 2011: Fall … Read More »NEWSLETTER ARCHIVE
Help Advance Myeloproliferative Neoplasms (MPN) Research from Home and Earn $100
MPN NEWS | July 7, 2021
The MPN Research Foundation is reaching out to the MPN patient community to raise awareness about an opportunity for patients 18 years of age or older with Myeloproliferative Neoplasms (MPN). Patients who qualify can support research by providing a one-time blood donation from home. The blood sample will be collected by a mobile medical professional… Read More »Help Advance Myeloproliferative Neoplasms (MPN) Research from Home and Earn $100
ASCO RELEASES VIDEOS OF EXPERTS DISCUSSING MPDS
MPN NEWS | May 3, 2021
December 2010 The American Society of Clinical Oncology (ASCO) recently released three videos of renowned MPD specialists discussing various topics related to MPDs. Drs. Ayalew Tefferi, William Vainchencker and James Vardiman contributed to the series. Click here to view videos
MPD CHAT ARCHIVES ASH ABSTRACTS
MPN NEWS | May 3, 2021
December 2010 Online chat and support group MPD-Chat has listed all abstracts presented at the recent American Society of Hematology meeting that are relevant to MPD/MPN. Take a look at the abstract as well as the discussion boards. Thanks to MPD Chat for compiling this list!
2009 GRANT ANNOUNCEMENT
MPN NEWS | April 30, 2021
The MPD Foundation is pleased to announce the recipients of our Research Alliance and New Investigator grants for 2009. This follows an extensive proposal review process conducted by our Scientific Advisory Board as well as additional MPD experts who gave generously of their time and expertise. Listed below are the grantee names, institutions and project… Read More »2009 GRANT ANNOUNCEMENT
A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS
MPN NEWS | April 30, 2021
This is an abstract that was presented at ASH’s annual meeting on Sunday, December 7, 2008: 4:45 PM 304-306-308 – South (Moscone Center) JAK2 V617F has been identified as a constitutive activating mutation in approximately half of patients with myelofibrosis (MF). MF, a myeloproliferative disorder comprised of primary myelofibrosis and the clinically indistinguishable entities of… Read More »A PHASE I STUDY OF XL019, A SELECTIVE JAK2 INHIBITOR, IN PATIENTS WITH PRIMARY MYELOFIBROSIS, POST-POLYCYTHEMIA VERA, OR POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS